This is an old revision of the document!


McGill Interdisciplinary Initiative in Infection and Immunity

The McGill Interdisciplinary Initiative in Infection and Immunity (MI4) is a Canadian research organization in Montreal, Quebec. It is based out of McGill University.

History

COVID-19

MI4 provided research funding related to COVID-19 through their “MI4 Emergency COVID-19 Research Funding” program.1) In particular, MI4 participated as a funding partner of the Canadian arm of the first randomized control trial (RCT) testing hydroxychloroquine for the post-exposure prevention of COVID-19, led by principal investigator David Boulware, which began on March 17, 2020.2)

Organization

Partners

Funding

Activities

MI4 Emergency COVID-19 Research Funding5)
MI4 ECRF Round 2
Lead investigators Project title
Nicole Basta Real-Time Tracking of COVID-19 Vaccine Development
Inés Colmegna, Amal Bessissow, David Meger Use of Technology to Improve Effects of Social Isolation on Hospitalized COVID-19 Patients (TIES-COVID)
Gonzalo Cosa Novel Small Molecule Antiviral Agents for Treatment of SARS-CoV-2 causing COVID 19 coronavirus disease: Target Identification and Structural Optimization
1) , 4) , 5)
Results of MI4 Emergency COVID-19 Research Funding. MI4. Retrieved May 16, 2023, from https://web.archive.org/web/20230516234033/https://www.mcgill.ca/mi4/mi4-supported-research/emergency-covid-19-research-funding
2)
Lofgren, S. M., Nicol, M. R., Bangdiwala, A. S., Pastick, K. A., Okafor, E. C., Skipper, C. P., Pullen, M. F., Engen, N., Abassi, M., Williams, D. A., Nascene, A. A., Axelrod, M. L., Lother, S. A., MacKenzie, L. J., Drobot, G., Marten, N., Cheng, M. P., Zarychanshi, R., Schwartz, I. S., & Silverman, M. J. (2020). Safety of Hydroxychloroquine among Outpatient Clinical Trial Participants for COVID-19. medRxiv. https://doi.org/10.1101/2020.07.16.20155531
Back to top